安派科(AnPac Bio)在美获得重要新型微型医疗设备专利 (英文)

自媒体 自媒体

[原文来自:www.11jj.com]

AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States

  [好文分享:www.11jj.com]

NEWS PROVIDED BY AnPac Bio-Medical Science Co., Ltd. 


SAN JOSE, Calif., March 24, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the allowance by  the United States Patent and Trademark Office on March 5, 2020, of a US patent application claiming an integrated and decomposable micro apparatus that can be used for site-specific delivery of a drug, a medical kit, a micro disease detection system, or even an auto-navigation system for in vivo applications.


Cancer Differentiation Analysis Technology


"As a leader in using biophysical properties to scan and detect changes in blood and other liquid samples, we wanted to make sure that our technology and patents also include our devices to have the option of being in vivo so that we can constantly test and detect changes in the in the human body," said Dr. Chris Yu, CEO and Chairman of AnPac Bio. "Due to our fundamental pending and issued patents in the US and many other jurisdictions covering the entire spectrum of disease detection, as well as micro surgical operations and drug release responses, intellectual properties of biophysical measurements with multi-functional micro- medical devices will have significant value in the future."


About AnPac Bio


AnPac Bio is a biotechnology company focused on early cancer screening and detection with two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio's CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.


For more information, please visit: https://www.Anpacbio.com.


For investor and media inquiries, please contact:


Company:
Phil Case, Marketing and Investor Relations
Email: phil_case@AnPacbio.com

Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Email: tina.xiao@ascent-ir.com   


Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; and our relationship with our major business partners and customers. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


转自prnewswire.com 起原 SOURCE AnPac Bio-Medical Science Co., Ltd.

本文由「华尔街俱乐部」介绍,敬请关注公家号: wallstreetclub

声明:本文仅代表作者个人概念,不构成投资定见,并不代表本平台立场。文中的论说和概念,敬请读者留意判断。

版权声明:「华尔街俱乐部」除发布原创市场投研申报外,亦致力于优良财经文章的交流分享。部门文章、图片和资料来自收集,版权归原创。推送时未能实时与原作者取得关系。若涉及版权问题,敬请原作者添加WSCHELP微信关系删除。感激授权使用!

免责声明:「华尔街俱乐部」竭力供给准确而靠得住的资讯,惟不保证绝对无误,资讯如有讹夺而令旁边承受损失(不论是否与侵权行为、订立契约或其他方面有关),本号概不负责。同时,「华尔街俱乐部」所供给之投资理会花样与建议,只可作为参考之用,并不构成要约、招揽、邀请、诱使、任何不论种类或形式之申述或订立任何建议及介绍,读者务请运用个人自力思虑能力自行作出投资决意,如因相关建议招致损失,概与「华尔街俱乐部」、编纂及记者无关。

华尔街俱乐部凝聚华尔街投行的高端资源,为中国民营企业“走出去”供给全方位的咨询人处事,包括企业赴美上市、计策投资、并购、私募路演和投资者关系等。在投资理念和手艺方面供给华尔街投行专家实战培训,为您进入华尔街铺设成功之路。




自媒体微信号:11jj扫描二维码关注公众号
爱八卦,爱爆料。
小编推荐
  1. NO.1 AI技术下的娱乐圈女星全都.avi了

    这是娱乐圈行动派——去酱 的第32篇《我去》 今天,我看了好几个女星的小黄片(封面) 这两天,有手艺人把杨幂的五官换到了《射雕英雄传》的黄蓉脸上(原朱茵饰)↓你们看了没?

  2. NO.2 剑三怎么抓马地点(剑三重制版马驹刷新点)

    龙子和麟驹天天的刷新纪律是 早上7点到11点是一轮 正午11点到15点是一轮 下昼15点到19点是一轮 晚上19点到23点是一轮 凌晨23点到03点是一轮 凌晨03点到07点是一轮 每轮刷新6只龙子麟驹各

  3. NO.3 明星大侦探甄完美谁扮演的 宋妍霏大跳热舞惊艳众人

    《明星大侦察》的nznd破冰演唱会,以及第六案是有关系的。个中,甄完美成为第五季里,最美的被害人。好多网友好奇,甄完美是谁饰演的?后认识到,甄完美饰演者其实宋妍霏。在节

  4. NO.4 李嘉诚纪念亡妻的庄月明楼,是风水宝地还是锁魂阴棺?

    对了!蜜桃哥哥看见很多小可爱们问,我新增的长文系列菜单栏在哪里,来来来,蜜桃哥哥手把手教你们回溯以往的长文系列。 首先进入 “圈内密探” 的公众号主页,然后

  5. NO.5 《火焰之纹章 风花雪月》三大势力学生能力介绍,你选好了吗?

    距离《火焰之纹章 风花雪月》发售还有一周的时间,然则网上的一些介入过测试的媒体与视频博主已经起头狂吹不止,被他们喻为史上最强的火纹续作。 首个媒体评分由Fami通给出,获

  6. NO.6 暗黑破坏神3武僧攻略有哪些(2019暗黑3武僧升级加点技能分析)

    今天小编就带人人从根源下手,具体认识一下这套BD的输出机制与弄法。 乌莲娜套简称捂脸,是使用爆裂掌作为首要危险的弄法,爆炸结果酷炫,群伤优势显着,在能打的动的前提下清

  7. NO.7 2019年暗黑3什么职业单刷最好最快(暗黑3十大单人冲榜主流玩法

    2.4版本点窜了好多内容,相信还有不少小伙伴对于本身职业所发生的转变摸不着思想吧。不外不消焦急不消担心,有了小编今天给你介绍的这套完整的六个职业的弄法攻略,相信必然可

  8. NO.8 超合金魂盖塔皇帝终于来了!盖塔战舰简直帅爆!

    关注wx公众号:涛哥测评,掌握玩具最新资讯 近日,万代超合金魂正式公布了超合金魂盖塔皇帝的先行官图,分体形态下的盖塔战舰也太帅了吧,这让我对合体的造型充满了

Copyright2018.依依自媒体资讯站,让大家及时掌握各行各业第一手资讯新闻!